Literature DB >> 6144889

Cyclosporin for pulmonary sarcoidosis.

A S Rebuck, C R Stiller, A C Braude, A Laupacis, R D Cohen, K R Chapman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6144889     DOI： 10.1016/s0140-6736(84)91411-9

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  6 in total

Review 1.  Current concepts in the management of sarcoidosis.

Authors:  M M Muthiah; J T Macfarlane
Journal:  Drugs       Date:  1990-08       Impact factor: 9.546

2.  Morphological and functional changes of pancreatic B cells in cyclosporin A-treated rats.

Authors:  U Helmchen; W E Schmidt; E G Siegel; W Creutzfeldt
Journal:  Diabetologia       Date:  1984-09       Impact factor: 10.122

Review 3.  Evidence-based therapy for cutaneous sarcoidosis.

Authors:  Christy B Doherty; Ted Rosen
Journal:  Drugs       Date:  2008       Impact factor: 9.546

4.  The effect of cyclosporine on immunization with tetanus and keyhole limpet hemocyanin (KLH) in humans.

Authors:  A G Palestine; F Roberge; B L Charous; H C Lane; A S Fauci; R B Nussenblatt
Journal:  J Clin Immunol       Date:  1985-03       Impact factor: 8.317

5.  In vitro effect of cyclosporin A on immunoglobulin production and concanavalin A induced suppression in primary biliary cirrhosis.

Authors:  M N Al-Aghbar; G J Alexander; K T Nouri-Aria; J Neuberger; A L Eddleston; R Williams
Journal:  Gut       Date:  1986-03       Impact factor: 23.059

6.  Very low-dose cyclosporin treatment of steroid-resistant interstitial pneumonitis associated with Sjögren's syndrome.

Authors:  H Ogasawara; M Sekiya; A Murashima; T Hishikawa; Y Tokano; I Sekigawa; N Iida; H Hashimoto; S Hirose
Journal:  Clin Rheumatol       Date:  1998       Impact factor: 2.980
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.